Drugs / SP-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07334249 | Dec 2025 → Jun 2026 overdue | major depressive disorder | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06526923 | Sep 2024 → Dec 2026 expected | cystic fibrosis | Spirovant Sciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06526923 ↗ |
| Action | Restore | “SP-101 restored CFTR-mediated chloride conductance” PMID 39155805 ↗ Aug 2024 |
| Modality | Gene therapy (AAV / viral vector) | “SP-101 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a human CFTR minigene” PMID 39155805 ↗ Aug 2024 |
| Route | Inhaled | “being investigated as an inhalation treatment for people with CF.” PMID 39155805 ↗ Aug 2024 |